Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Dasatinib Sensitivity Signature	9
Overall Study	STARTED	SRC Pathway Activity Signature	8
Overall Study	STARTED	Dasatinib Target Index	13
Overall Study	STARTED	MEK Pathway Activity Predictor Positive	0
Overall Study	STARTED	MEK Pathway Predictor Negative	0
Overall Study	COMPLETED	Dasatinib Sensitivity Signature	9
Overall Study	COMPLETED	SRC Pathway Activity Signature	8
Overall Study	COMPLETED	Dasatinib Target Index	13
Overall Study	COMPLETED	MEK Pathway Activity Predictor Positive	0
Overall Study	COMPLETED	MEK Pathway Predictor Negative	0
Overall Study	NOT COMPLETED	Dasatinib Sensitivity Signature	0
Overall Study	NOT COMPLETED	SRC Pathway Activity Signature	0
Overall Study	NOT COMPLETED	Dasatinib Target Index	0
Overall Study	NOT COMPLETED	MEK Pathway Activity Predictor Positive	0
Overall Study	NOT COMPLETED	MEK Pathway Predictor Negative	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00780676/flow